Radical neck dissection.

P E Robin

doi:10.1111/j.1365-2273.1976.tb00888.x

Home/Archive/PubMed

PubMed · 1031356

Radical neck dissection.

P E Robin

View original source ↗Export metadata ↓

Abstract

Radical neck dissection was described in 1906, and the following half century saw it being increasingly accepted without any significant change. More recently a number of differing concepts have arisen. While the value of the original radical operation is established, the more recent modifications are not yet substantiated by proper trials.

Explore related subjects

Carcinoma, Squamous Cell Head and Neck Neoplasms Humans Lymphatic Metastasis Neck Dissection Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

P E Robin. 1976. Radical neck dissection.. https://doi.org/10.1111/j.1365-2273.1976.tb00888.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2017

Nonpromoter methylation of the CDKN2A gene with active transcription is associated with improved locoregional control in laryngeal squamous cell carcinoma.

We previously reported a novel association between CDKN2A nonpromoter methylation and transcription (ARF/INK4a) in human papillomavirus associated oropharyngeal tumors. In this study we assessed whether nonpromoter CDKN2A methylation in laryngeal squamous cell carcinomas (LXSCC) conferred a similar association with transcription that predicted patient outcome. We compared DNA methylation and ARF/INK4a RNA expression levels for the CDKN2A locus using the Illumina HumanMethylation27 beadchip and RT-PCR in 43 LXSCC tumor samples collected from a prospective study of head and neck cancer patients treated at Montefiore Medical Center (MMC). Validation was performed using RNAseq data on 111 LXSCC tumor samples from the Cancer Genome Atlas (TCGA). The clinical relevance of combined nonpromoter CDKN2A methylation and transcription was assessed by multivariate Cox regression for locoregional recurrence on a subset of 69 LXSCC patients with complete clinicopathologic data from the MMC and TCGA cohorts. We found evidence of CDKN2A nonpromoter hypermethylation in a third of LXSCC from our MMC cohort, which was significantly associated with increased ARF and INK4a RNA expression (Wilcoxon rank-sum, P = 0.007 and 0.003, respectively). A similar association was confirmed in TCGA samples (Wilcoxon rank-sum test P < 0.0001 for ARF and INK4a). Patients with CDKN2A hypermethylation or high ARF/INK4a expression were significantly less likely to develop a locoregional recurrence compared to those with neither of the features, independent of other clinicopatholgic risk factors (adjusted hazard ratio=0.21, 95% confidence interval:0.05-0.81). These results support the conclusion that CDKN2A nonpromoter methylation is associated with increased ARF and INK4a RNA expression, and improved locoregional control in LXSCC.

Carcinoma, Squamous Cell↗

PubMed1992

Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line.

To elucidate the mechanism of the synergistic cytotoxicity of 5-fluorouracil (5-FU) and cis-diamminedichloroplatinum(II) (CDDP), we studied the interaction of these agents using a human squamous carcinoma cell line (HST-1). Exposure to 5-FU for 24 h and to CDDP for 1 h produced a 50% inhibitory concentration of 1.0 micrograms/ml (7.7 microM) and 2.5 micrograms/ml (8.3 microM), respectively. The cytotoxic action of CDDP was augmented, and a greater than additive effect was observed when the cells were exposed to 5-FU (1.0 micrograms/ml; 7.7 microM) for 24 h before the CDDP treatment. This synergistic activity was maximal when the interval between 5-FU and CDDP exceeded 24 h. In contrast, the cytotoxicity of CDDP was attenuated when it preceded the exposure to 5-FU. Thymidine did not alter the 5-FU-CDDP interaction. Evaluation of the kinetics of the removal of DNA interstrand cross-links, measured by alkaline elution, showed a significant reduction of this removal in the cells exposed to 5-FU followed by CDDP with a drug-free interval of 48 h, as compared with cells exposed to CDDP alone, or to 5-FU immediately followed by CDDP, although no differences were found in the formation of DNA interstrand cross-links by CDDP among these cells. No significant differences in the accumulation of intracellular platinum were detected by atomic absorption spectrophotometry. These findings suggest that 5-FU modulates the repair of platinum-DNA adducts, thereby potentiating the antitumor activity of CDDP.

Carcinoma, Squamous Cell↗

PubMed1992

Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells.

Five of six human squamous cell carcinoma (SCC) cell lines characterized as radiation sensitive (SQ-38, SCC-9, SQ-9G) or radiation resistant (SQ-20B, SCC-35, JSQ-3) exhibited alterations of the p53 gene. The point mutations and a deletion were detected by using single-stranded conformational polymorphism analysis and polymerase chain reaction-direct sequencing. Interestingly, three of three radiation-sensitive and two of three radiation-resistant cell lines revealed mutations in the p53 gene. Point mutations were located in exons 4, 6, and 8 (at codons 72 and 298 in JSQ-3; 273 in SCC-35; 196 in SQ-38), and deletions consisted of 32 base pairs between codons 274 and 285 in SCC-9 and 1 base pair at codon 271 in SQ-9G. Three mutations resulted in substitutions for an arginine residue. Immunocytochemical analysis confirmed p53 protein overexpression in SCC-35 cells which contained a missense mutation at codon 273. In contrast to previous studies which linked alterations in ras, myc, and raf expression with radiation resistance, this study indicates that mutations in the tumor suppressor gene, p53, do not directly correlate with such resistance.

Carcinoma, Squamous Cell↗